Drug survival of metformin in patients with hidradenitis suppurativa

Abstract

Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.